Retour

Breast Cancer Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

News breast cancer

The breast cancer pipeline is robust with over 100 active players working on 120+ pipeline drugs. Key companies like Ambrx, Merus, and Regeneron are evaluating promising therapies to improve the treatment landscape.

GlobeNewswire Inc. • 01/10/2024 à 19:00:00
Merus N.V. Common Shares
Adresse: YALELAAN 62
Code postal: 3584 CM
Ville: 3584 CM UTRECHT
Region: P7
Numéro de telephone: 31 030 253 8800
Site internet: https://www.merus.nl
Status: Active
Info de l'entreprise

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Date de référencement2016-05-19
MarchéStocks
LocaleUS
Echange principalXNAS
TypeCS
DeviseUSD
CIK0001651311
Market Cap3,589,235,405 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employés229
Share Class Shares Outstanding68210000
Weighted Shares Outstanding68210479
Round Lot100
Date de mise à jour2024-10-11
Stats
5 derniers jours
11-10
10-10
4-10
3-10
2-10
Dernier
53.39
52.62
51.79
48.435
50.51
Variation
1.46%
1.29%
6.93%
-4.11%
0.85%
Ouverture
52.62
51.948
48.435
50.51
50.085
Plus haut
53.635
52.839
51.831
50.51
50.999
Plus bas
53.625
52.813
51.795
50.51
50.966
Historique
PériodeVarPlus hautPlus bas
1 semaine
2.78%
52.839
52.813
1 mois
6.13%
50.515
47.665
3 mois
-4.92%
57.96
47.665
6 mois
25.39%
42.7114
39.27
1 an
154.36%
21.11
19.805
3 ans
74.53%
31.71
12.03
5 ans
214.06%
17
10.18
10 ans
447.59%
10.735
7.255
Bilans
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-07 2023-11-02 UNPUB
Assets 338,520,000 363,624,000 492,186,000 UNPUB
Current Assets 258,164,000 283,125,000 404,832,000 UNPUB
Current Liabilities 75,087,000 65,849,000 64,318,000 UNPUB
Equity 217,523,000 257,405,000 393,388,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 217,523,000 257,405,000 393,388,000 UNPUB
Liabilities 120,997,000 106,219,000 98,798,000 UNPUB
Liabilities And Equity 338,520,000 363,624,000 492,186,000 UNPUB
Noncurrent Assets 80,356,000 80,499,000 87,354,000 UNPUB
Noncurrent Liabilities 45,910,000 40,370,000 34,480,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-07 2023-11-02 UNPUB
Exchange Gains/Losses -171,000 -1,343,000 -2,134,000 UNPUB
Net Cash Flow -45,104,000 -1,480,000 140,760,000 UNPUB
Net Cash Flow, Continuing -44,933,000 -137,000 142,894,000 UNPUB
Net Cash Flow From Financing Activities 217,000 65,967,000 162,402,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 217,000 65,967,000 162,402,000 UNPUB
Net Cash Flow From Investing Activities -8,407,000 -24,518,000 8,022,000 UNPUB
Net Cash Flow From Investing Activities, Continuing -8,407,000 -24,518,000 8,022,000 UNPUB
Net Cash Flow From Operating Activities -36,743,000 -41,586,000 -27,530,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -36,743,000 -41,586,000 -27,530,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-07 2023-11-02 UNPUB
Comprehensive Income/Loss -35,499,000 -32,538,000 -33,734,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -35,499,000 -32,538,000 -33,734,000 UNPUB
Other Comprehensive Income/Loss 4,242,000 -32,538,000 -33,734,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-07 2023-11-02 UNPUB
Basic Earnings Per Share -1 -1 0 UNPUB
Benefits Costs and Expenses 53,697,000 41,015,000 32,927,000 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 53,697,000 41,015,000 32,927,000 UNPUB
Diluted Earnings Per Share -1 -1 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -39,741,000 -32,033,000 -23,012,000 UNPUB
Income/Loss From Continuing Operations Before Tax -40,198,000 -30,539,000 -21,894,000 UNPUB
Income Tax Expense/Benefit -457,000 1,494,000 1,118,000 UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -39,741,000 -32,033,000 -23,012,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -39,741,000 -32,033,000 -23,012,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -39,741,000 -32,033,000 -23,012,000 UNPUB
Operating Expenses 50,251,000 44,361,000 49,401,000 UNPUB
Operating Income/Loss -36,752,000 -33,885,000 -38,368,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 13,499,000 10,476,000 11,033,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-08 2022-11-03 2023-02-28
Assets 417,500,000 444,793,000 414,990,000 376,542,000
Current Assets 379,733,000 398,825,000 368,199,000 306,443,000
Current Liabilities 61,523,000 60,263,000 64,150,000 78,926,000
Equity 297,473,000 326,609,000 298,777,000 247,055,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 297,473,000 326,609,000 298,777,000 247,055,000
Liabilities 120,027,000 118,184,000 116,213,000 129,487,000
Liabilities And Equity 417,500,000 444,793,000 414,990,000 376,542,000
Noncurrent Assets 37,767,000 45,968,000 46,791,000 70,099,000
Noncurrent Liabilities 0 0 52,063,000 50,561,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-08 2022-11-03 2023-02-28
Exchange Gains/Losses -377,000 -799,000 10,042,000 -4,952,000
Net Cash Flow -46,862,000 19,720,000 -22,479,000 -93,310,000
Net Cash Flow, Continuing -46,485,000 20,519,000 -32,521,000 -88,358,000
Net Cash Flow From Financing Activities 879,000 48,199,000 9,876,000 58,739,000
Net Cash Flow From Financing Activities, Continuing 879,000 48,199,000 9,876,000 58,739,000
Net Cash Flow From Investing Activities -967,000 4,054,000 -1,141,000 2,802,000
Net Cash Flow From Investing Activities, Continuing -967,000 4,054,000 -1,141,000 2,802,000
Net Cash Flow From Operating Activities -46,397,000 -31,734,000 -41,256,000 -149,899,000
Net Cash Flow From Operating Activities, Continuing -46,397,000 -31,734,000 -41,256,000 -149,899,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-08 2022-11-03 2023-02-28
Comprehensive Income/Loss -24,941,000 -25,635,000 -44,090,000 -152,421,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -18,893,000 -5,714,000 -44,090,000 -152,421,000
Other Comprehensive Income/Loss 0 0 -44,090,000 -21,227,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-08 2022-11-03 2023-02-28
Basic Earnings Per Share 0 0 -1 -3
Benefits Costs and Expenses 30,434,000 18,267,000 30,869,000 171,821,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 30,434,000 18,267,000 30,869,000 171,821,000
Diluted Earnings Per Share 0 0 -1 -3
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -18,893,000 -5,714,000 -24,615,000 -131,194,000
Income/Loss From Continuing Operations Before Tax -18,779,000 -5,583,000 -24,288,000 -130,235,000
Income Tax Expense/Benefit 114,000 131,000 327,000 959,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -18,893,000 -5,714,000 -24,615,000 -131,194,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -18,893,000 -5,714,000 -24,615,000 -131,194,000
Net Income/Loss Available To Common Stockholders, Basic -18,893,000 -5,714,000 -24,615,000 -131,194,000
Operating Expenses 38,728,000 43,791,000 54,776,000 201,624,000
Operating Income/Loss -27,073,000 -31,107,000 -48,195,000 -160,038,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 11,655,000 12,684,000 6,581,000 41,586,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-05 2021-11-02 2022-02-28
Assets 397,949,000 379,583,000 355,927,000 456,600,000
Current Assets 386,124,000 366,994,000 319,722,000 424,179,000
Current Liabilities 52,955,000 64,407,000 71,533,000 71,898,000
Equity 236,537,000 219,087,000 205,769,000 316,201,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 236,537,000 219,087,000 205,769,000 316,201,000
Liabilities 161,412,000 160,496,000 150,158,000 140,399,000
Liabilities And Equity 397,949,000 379,583,000 355,927,000 456,600,000
Noncurrent Assets 11,825,000 12,589,000 36,205,000 32,421,000
Noncurrent Liabilities 0 0 78,625,000 68,501,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-05 2021-11-02 2022-02-28
Exchange Gains/Losses -3,070,000 1,043,000 2,046,000 2,761,000
Net Cash Flow 164,056,000 -15,666,000 -152,351,000 78,466,000
Net Cash Flow, Continuing 167,126,000 -16,709,000 -154,397,000 75,705,000
Net Cash Flow From Financing Activities 150,457,000 1,861,000 2,595,000 281,955,000
Net Cash Flow From Financing Activities, Continuing 150,457,000 1,861,000 2,595,000 281,955,000
Net Cash Flow From Investing Activities -2,674,000 5,727,000 -133,917,000 -146,623,000
Net Cash Flow From Investing Activities, Continuing -2,674,000 5,727,000 -133,917,000 -146,623,000
Net Cash Flow From Operating Activities 19,343,000 -24,297,000 -23,075,000 -59,627,000
Net Cash Flow From Operating Activities, Continuing 19,343,000 -24,297,000 -23,075,000 -59,627,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-05 2021-11-02 2022-02-28
Comprehensive Income/Loss -19,545,000 -23,913,000 -20,244,000 -85,108,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -10,154,000 -27,388,000 -20,244,000 -85,108,000
Other Comprehensive Income/Loss 0 0 -20,244,000 -18,292,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-05 2021-11-02 2022-02-28
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses 18,455,000 39,705,000 28,533,000 115,684,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 18,455,000 39,705,000 28,533,000 115,684,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -10,154,000 -27,388,000 -14,853,000 -66,816,000
Income/Loss From Continuing Operations Before Tax -10,105,000 -27,326,000 -14,864,000 -66,577,000
Income Tax Expense/Benefit 49,000 62,000 -11,000 239,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -10,154,000 -27,388,000 -14,853,000 -66,816,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -10,154,000 -27,388,000 -14,853,000 -66,816,000
Net Income/Loss Available To Common Stockholders, Basic -10,154,000 -27,388,000 -14,853,000 -66,816,000
Operating Expenses 30,139,000 35,181,000 36,189,000 139,083,000
Operating Income/Loss -21,789,000 -22,802,000 -22,520,000 -89,976,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 8,350,000 12,379,000 13,669,000 49,107,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-06 2020-11-05 2021-03-16
Assets 237,962,000 223,661,000 213,493,000 231,217,000
Current Assets 225,451,000 211,404,000 201,316,000 217,993,000
Current Liabilities 35,567,000 38,315,000 45,431,000 46,746,000
Equity 114,586,000 100,296,000 84,501,000 102,263,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 114,586,000 100,296,000 84,501,000 102,263,000
Liabilities 123,376,000 123,365,000 128,992,000 128,954,000
Liabilities And Equity 237,962,000 223,661,000 213,493,000 231,217,000
Noncurrent Assets 12,511,000 12,257,000 12,177,000 13,224,000
Noncurrent Liabilities 0 0 83,561,000 82,208,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-06 2020-11-05 2021-03-16
Exchange Gains/Losses -3,002,000 1,895,000 4,874,000 7,337,000
Net Cash Flow -31,812,000 -13,712,000 -12,909,000 -34,530,000
Net Cash Flow, Continuing -28,810,000 -15,607,000 -17,783,000 -41,867,000
Net Cash Flow From Financing Activities 438,000 291,000 22,000 39,520,000
Net Cash Flow From Financing Activities, Continuing 438,000 291,000 22,000 39,520,000
Net Cash Flow From Investing Activities -3,988,000 2,710,000 -6,108,000 -1,486,000
Net Cash Flow From Investing Activities, Continuing -3,988,000 2,710,000 -6,108,000 -1,486,000
Net Cash Flow From Operating Activities -25,260,000 -18,608,000 -11,697,000 -79,901,000
Net Cash Flow From Operating Activities, Continuing -25,260,000 -18,608,000 -11,697,000 -79,901,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-06 2020-11-05 2021-03-16
Comprehensive Income/Loss -19,607,000 -15,773,000 -18,661,000 -78,028,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -16,500,000 -17,974,000 -18,661,000 -78,028,000
Other Comprehensive Income/Loss 0 0 -18,661,000 7,485,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-06 2020-11-05 2021-03-16
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses 22,704,000 23,999,000 31,468,000 114,953,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 22,704,000 23,999,000 31,468,000 114,953,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -16,500,000 -17,974,000 -23,075,000 -85,513,000
Income/Loss From Continuing Operations Before Tax -16,403,000 -17,943,000 -22,898,000 -85,010,000
Income Tax Expense/Benefit 97,000 31,000 177,000 503,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -16,500,000 -17,974,000 -23,075,000 -85,513,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -16,500,000 -17,974,000 -23,075,000 -85,513,000
Net Income/Loss Available To Common Stockholders, Basic -16,500,000 -17,974,000 -23,075,000 -85,513,000
Operating Expenses 25,869,000 21,752,000 26,674,000 105,821,000
Operating Income/Loss -19,568,000 -15,696,000 -18,104,000 -75,878,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 6,301,000 6,056,000 8,570,000 29,943,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2020-03-16
Assets UNPUB UNPUB UNPUB 263,376,000
Current Assets UNPUB UNPUB UNPUB 247,368,000
Current Liabilities UNPUB UNPUB UNPUB 36,787,000
Equity UNPUB UNPUB UNPUB 131,300,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Equity Attributable To Parent UNPUB UNPUB UNPUB 131,300,000
Liabilities UNPUB UNPUB UNPUB 132,076,000
Liabilities And Equity UNPUB UNPUB UNPUB 263,376,000
Noncurrent Assets UNPUB UNPUB UNPUB 16,008,000
Noncurrent Liabilities UNPUB UNPUB UNPUB 95,289,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2020-03-16
Exchange Gains/Losses UNPUB UNPUB UNPUB -2,273,000
Net Cash Flow UNPUB UNPUB UNPUB 33,083,000
Net Cash Flow, Continuing UNPUB UNPUB UNPUB 35,356,000
Net Cash Flow From Financing Activities UNPUB UNPUB UNPUB 74,232,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB UNPUB 74,232,000
Net Cash Flow From Investing Activities UNPUB UNPUB UNPUB 24,172,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB UNPUB 24,172,000
Net Cash Flow From Operating Activities UNPUB UNPUB UNPUB -63,048,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB UNPUB -63,048,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2020-03-16
Comprehensive Income/Loss UNPUB UNPUB UNPUB -56,459,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB -56,459,000
Other Comprehensive Income/Loss UNPUB UNPUB UNPUB -1,308,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2020-03-16
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB 86,090,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB 86,090,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB UNPUB -55,151,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB UNPUB -54,957,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 194,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB UNPUB UNPUB -55,151,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Net Income/Loss Attributable To Parent UNPUB UNPUB UNPUB -55,151,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB UNPUB -55,151,000
Operating Expenses UNPUB UNPUB UNPUB 89,790,000
Operating Income/Loss UNPUB UNPUB UNPUB -58,657,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB UNPUB 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB UNPUB 0
Revenues UNPUB UNPUB UNPUB 31,133,000
Calendrier économique
11 Octobre 2024 (heure UTC) Actuel Précédent Consensus
★
15:30
United States
OCT 08
2900.000
3800.000
★
15:30
United States
OCT 08
43100.000
43200.000
★
15:30
United States
OCT 08
36100.000
-7200.000
★
15:30
United States
OCT 08
190600.000
159600.000
★
15:30
United States
OCT 08
278200.000
299900.000
★★
15:30
United States
OCT 08
13300.000
16100.000
★
15:30
United States
OCT 08
-123600.000
-109000.000
★
15:30
United States
OCT 08
-5600.000
7500.000
★
15:30
United States
OCT 08
54700.000
56900.000
★
15:30
United States
OCT 08
-51200.000
-73700.000
★
15:30
United States
OCT 08
-13500.000
-6100.000
★★
14:00
United States
SEP
-380100000000.000
61000000000.000
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:MRUS240920C00050000 OCASPS Call American 100 50 BATO 2024-09-20
O:MRUS240920C00055000 OCASPS Call American 100 55 BATO 2024-09-20
O:MRUS240920C00060000 OCASPS Call American 100 60 BATO 2024-09-20
O:MRUS240920C00065000 OCASPS Call American 100 65 BATO 2024-09-20
O:MRUS240920C00070000 OCASPS Call American 100 70 BATO 2024-09-20
O:MRUS240920C00075000 OCASPS Call American 100 75 BATO 2024-09-20
O:MRUS240920C00080000 OCASPS Call American 100 80 BATO 2024-09-20
O:MRUS240920C00085000 OCASPS Call American 100 85 BATO 2024-09-20
O:MRUS240920C00090000 OCASPS Call American 100 90 BATO 2024-09-20
O:MRUS240920P00050000 OPASPS Put American 100 50 BATO 2024-09-20
O:MRUS240920P00055000 OPASPS Put American 100 55 BATO 2024-09-20
O:MRUS240920P00060000 OPASPS Put American 100 60 BATO 2024-09-20
O:MRUS240920P00065000 OPASPS Put American 100 65 BATO 2024-09-20
O:MRUS240920P00070000 OPASPS Put American 100 70 BATO 2024-09-20
O:MRUS240920P00075000 OPASPS Put American 100 75 BATO 2024-09-20
O:MRUS240920P00080000 OPASPS Put American 100 80 BATO 2024-09-20
O:MRUS240920P00085000 OPASPS Put American 100 85 BATO 2024-09-20
O:MRUS240920P00090000 OPASPS Put American 100 90 BATO 2024-09-20
O:MRUS240920C00017500 OCASPS Call American 100 17.5 BATO 2024-09-20
O:MRUS240920C00020000 OCASPS Call American 100 20 BATO 2024-09-20
O:MRUS240920C00022500 OCASPS Call American 100 22.5 BATO 2024-09-20
O:MRUS240920C00025000 OCASPS Call American 100 25 BATO 2024-09-20
O:MRUS240920C00030000 OCASPS Call American 100 30 BATO 2024-09-20
O:MRUS240920C00035000 OCASPS Call American 100 35 BATO 2024-09-20
O:MRUS240920C00040000 OCASPS Call American 100 40 BATO 2024-09-20
O:MRUS240920C00045000 OCASPS Call American 100 45 BATO 2024-09-20
O:MRUS240920P00017500 OPASPS Put American 100 17.5 BATO 2024-09-20
O:MRUS240920P00020000 OPASPS Put American 100 20 BATO 2024-09-20
O:MRUS240920P00022500 OPASPS Put American 100 22.5 BATO 2024-09-20
O:MRUS240920P00025000 OPASPS Put American 100 25 BATO 2024-09-20
O:MRUS240920P00030000 OPASPS Put American 100 30 BATO 2024-09-20
O:MRUS240920P00035000 OPASPS Put American 100 35 BATO 2024-09-20
O:MRUS240920P00040000 OPASPS Put American 100 40 BATO 2024-09-20
O:MRUS240920P00045000 OPASPS Put American 100 45 BATO 2024-09-20
O:MRUS240719C00022500 OCASPS Call American 100 22.5 BATO 2024-07-19
O:MRUS240719P00022500 OPASPS Put American 100 22.5 BATO 2024-07-19
O:MRUS240719C00025000 OCASPS Call American 100 25 BATO 2024-07-19
O:MRUS240719C00030000 OCASPS Call American 100 30 BATO 2024-07-19
O:MRUS240719C00035000 OCASPS Call American 100 35 BATO 2024-07-19
O:MRUS240719C00040000 OCASPS Call American 100 40 BATO 2024-07-19
O:MRUS240719C00045000 OCASPS Call American 100 45 BATO 2024-07-19
O:MRUS240719C00050000 OCASPS Call American 100 50 BATO 2024-07-19
O:MRUS240719C00055000 OCASPS Call American 100 55 BATO 2024-07-19
O:MRUS240719C00060000 OCASPS Call American 100 60 BATO 2024-07-19
O:MRUS240719C00065000 OCASPS Call American 100 65 BATO 2024-07-19
O:MRUS240719C00070000 OCASPS Call American 100 70 BATO 2024-07-19
O:MRUS240719P00025000 OPASPS Put American 100 25 BATO 2024-07-19
O:MRUS240719P00030000 OPASPS Put American 100 30 BATO 2024-07-19
O:MRUS240719P00035000 OPASPS Put American 100 35 BATO 2024-07-19
O:MRUS240719P00040000 OPASPS Put American 100 40 BATO 2024-07-19
O:MRUS240719P00045000 OPASPS Put American 100 45 BATO 2024-07-19
O:MRUS240719P00050000 OPASPS Put American 100 50 BATO 2024-07-19
O:MRUS240719P00055000 OPASPS Put American 100 55 BATO 2024-07-19
O:MRUS240719P00060000 OPASPS Put American 100 60 BATO 2024-07-19
O:MRUS240719P00065000 OPASPS Put American 100 65 BATO 2024-07-19
O:MRUS240719P00070000 OPASPS Put American 100 70 BATO 2024-07-19
O:MRUS240621C00045000 OCASPS Call American 100 45 BATO 2024-06-21
O:MRUS240621C00050000 OCASPS Call American 100 50 BATO 2024-06-21
O:MRUS240621C00055000 OCASPS Call American 100 55 BATO 2024-06-21
O:MRUS240621C00060000 OCASPS Call American 100 60 BATO 2024-06-21
O:MRUS240621C00065000 OCASPS Call American 100 65 BATO 2024-06-21
O:MRUS240621C00070000 OCASPS Call American 100 70 BATO 2024-06-21
O:MRUS240621C00075000 OCASPS Call American 100 75 BATO 2024-06-21
O:MRUS240621P00045000 OPASPS Put American 100 45 BATO 2024-06-21
O:MRUS240621P00050000 OPASPS Put American 100 50 BATO 2024-06-21
O:MRUS240621P00055000 OPASPS Put American 100 55 BATO 2024-06-21
O:MRUS240621P00060000 OPASPS Put American 100 60 BATO 2024-06-21
O:MRUS240621P00065000 OPASPS Put American 100 65 BATO 2024-06-21
O:MRUS240621P00070000 OPASPS Put American 100 70 BATO 2024-06-21
O:MRUS240621P00075000 OPASPS Put American 100 75 BATO 2024-06-21
O:MRUS240621C00012500 OCASPS Call American 100 12.5 BATO 2024-06-21
O:MRUS240621C00015000 OCASPS Call American 100 15 BATO 2024-06-21
O:MRUS240621C00017500 OCASPS Call American 100 17.5 BATO 2024-06-21
O:MRUS240621C00020000 OCASPS Call American 100 20 BATO 2024-06-21
O:MRUS240621C00022500 OCASPS Call American 100 22.5 BATO 2024-06-21
O:MRUS240621C00025000 OCASPS Call American 100 25 BATO 2024-06-21
O:MRUS240621C00030000 OCASPS Call American 100 30 BATO 2024-06-21
O:MRUS240621C00035000 OCASPS Call American 100 35 BATO 2024-06-21
O:MRUS240621C00040000 OCASPS Call American 100 40 BATO 2024-06-21
O:MRUS240621P00012500 OPASPS Put American 100 12.5 BATO 2024-06-21
O:MRUS240621P00015000 OPASPS Put American 100 15 BATO 2024-06-21
O:MRUS240621P00017500 OPASPS Put American 100 17.5 BATO 2024-06-21
O:MRUS240621P00020000 OPASPS Put American 100 20 BATO 2024-06-21
O:MRUS240621P00022500 OPASPS Put American 100 22.5 BATO 2024-06-21
O:MRUS240621P00025000 OPASPS Put American 100 25 BATO 2024-06-21
O:MRUS240621P00030000 OPASPS Put American 100 30 BATO 2024-06-21
O:MRUS240621P00035000 OPASPS Put American 100 35 BATO 2024-06-21
O:MRUS240621P00040000 OPASPS Put American 100 40 BATO 2024-06-21
O:MRUS240517C00025000 OCASPS Call American 100 25 BATO 2024-05-17
O:MRUS240517C00030000 OCASPS Call American 100 30 BATO 2024-05-17
O:MRUS240517C00035000 OCASPS Call American 100 35 BATO 2024-05-17
O:MRUS240517C00040000 OCASPS Call American 100 40 BATO 2024-05-17
O:MRUS240517C00045000 OCASPS Call American 100 45 BATO 2024-05-17
O:MRUS240517C00050000 OCASPS Call American 100 50 BATO 2024-05-17
O:MRUS240517C00055000 OCASPS Call American 100 55 BATO 2024-05-17
O:MRUS240517C00060000 OCASPS Call American 100 60 BATO 2024-05-17
O:MRUS240517C00065000 OCASPS Call American 100 65 BATO 2024-05-17
O:MRUS240517C00070000 OCASPS Call American 100 70 BATO 2024-05-17
O:MRUS240517P00025000 OPASPS Put American 100 25 BATO 2024-05-17
O:MRUS240517P00030000 OPASPS Put American 100 30 BATO 2024-05-17
O:MRUS240517P00035000 OPASPS Put American 100 35 BATO 2024-05-17
O:MRUS240517P00040000 OPASPS Put American 100 40 BATO 2024-05-17
O:MRUS240517P00045000 OPASPS Put American 100 45 BATO 2024-05-17
O:MRUS240517P00050000 OPASPS Put American 100 50 BATO 2024-05-17
O:MRUS240517P00055000 OPASPS Put American 100 55 BATO 2024-05-17
O:MRUS240517P00060000 OPASPS Put American 100 60 BATO 2024-05-17
O:MRUS240517P00065000 OPASPS Put American 100 65 BATO 2024-05-17
O:MRUS240517P00070000 OPASPS Put American 100 70 BATO 2024-05-17
O:MRUS240419C00065000 OCASPS Call American 100 65 BATO 2024-04-19
O:MRUS240419C00070000 OCASPS Call American 100 70 BATO 2024-04-19
O:MRUS240419C00075000 OCASPS Call American 100 75 BATO 2024-04-19
O:MRUS240419P00065000 OPASPS Put American 100 65 BATO 2024-04-19
O:MRUS240419P00070000 OPASPS Put American 100 70 BATO 2024-04-19
O:MRUS240419P00075000 OPASPS Put American 100 75 BATO 2024-04-19
O:MRUS240419C00022500 OCASPS Call American 100 22.5 BATO 2024-04-19
O:MRUS240419C00025000 OCASPS Call American 100 25 BATO 2024-04-19
O:MRUS240419C00030000 OCASPS Call American 100 30 BATO 2024-04-19
O:MRUS240419C00035000 OCASPS Call American 100 35 BATO 2024-04-19
O:MRUS240419C00040000 OCASPS Call American 100 40 BATO 2024-04-19
O:MRUS240419C00045000 OCASPS Call American 100 45 BATO 2024-04-19
O:MRUS240419C00050000 OCASPS Call American 100 50 BATO 2024-04-19
O:MRUS240419C00055000 OCASPS Call American 100 55 BATO 2024-04-19
O:MRUS240419C00060000 OCASPS Call American 100 60 BATO 2024-04-19
O:MRUS240419P00022500 OPASPS Put American 100 22.5 BATO 2024-04-19
O:MRUS240419P00025000 OPASPS Put American 100 25 BATO 2024-04-19
O:MRUS240419P00030000 OPASPS Put American 100 30 BATO 2024-04-19
O:MRUS240419P00035000 OPASPS Put American 100 35 BATO 2024-04-19
O:MRUS240419P00040000 OPASPS Put American 100 40 BATO 2024-04-19
O:MRUS240419P00045000 OPASPS Put American 100 45 BATO 2024-04-19
O:MRUS240419P00050000 OPASPS Put American 100 50 BATO 2024-04-19
O:MRUS240419P00055000 OPASPS Put American 100 55 BATO 2024-04-19
O:MRUS240419P00060000 OPASPS Put American 100 60 BATO 2024-04-19
O:MRUS240315C00055000 OCASPS Call American 100 55 BATO 2024-03-15
O:MRUS240315C00060000 OCASPS Call American 100 60 BATO 2024-03-15
O:MRUS240315C00065000 OCASPS Call American 100 65 BATO 2024-03-15
O:MRUS240315C00070000 OCASPS Call American 100 70 BATO 2024-03-15
O:MRUS240315C00075000 OCASPS Call American 100 75 BATO 2024-03-15
O:MRUS240315P00055000 OPASPS Put American 100 55 BATO 2024-03-15
O:MRUS240315P00060000 OPASPS Put American 100 60 BATO 2024-03-15
O:MRUS240315P00065000 OPASPS Put American 100 65 BATO 2024-03-15
O:MRUS240315P00070000 OPASPS Put American 100 70 BATO 2024-03-15
O:MRUS240315P00075000 OPASPS Put American 100 75 BATO 2024-03-15
O:MRUS240315C00045000 OCASPS Call American 100 45 BATO 2024-03-15
O:MRUS240315C00050000 OCASPS Call American 100 50 BATO 2024-03-15
O:MRUS240315P00045000 OPASPS Put American 100 45 BATO 2024-03-15
O:MRUS240315P00050000 OPASPS Put American 100 50 BATO 2024-03-15
O:MRUS240315C00012500 OCASPS Call American 100 12.5 BATO 2024-03-15
O:MRUS240315P00012500 OPASPS Put American 100 12.5 BATO 2024-03-15
O:MRUS240315C00015000 OCASPS Call American 100 15 BATO 2024-03-15
O:MRUS240315C00017500 OCASPS Call American 100 17.5 BATO 2024-03-15
O:MRUS240315C00020000 OCASPS Call American 100 20 BATO 2024-03-15
O:MRUS240315C00022500 OCASPS Call American 100 22.5 BATO 2024-03-15
O:MRUS240315C00025000 OCASPS Call American 100 25 BATO 2024-03-15
O:MRUS240315C00030000 OCASPS Call American 100 30 BATO 2024-03-15
O:MRUS240315C00035000 OCASPS Call American 100 35 BATO 2024-03-15
O:MRUS240315C00040000 OCASPS Call American 100 40 BATO 2024-03-15
O:MRUS240315P00015000 OPASPS Put American 100 15 BATO 2024-03-15
O:MRUS240315P00017500 OPASPS Put American 100 17.5 BATO 2024-03-15
O:MRUS240315P00020000 OPASPS Put American 100 20 BATO 2024-03-15
O:MRUS240315P00022500 OPASPS Put American 100 22.5 BATO 2024-03-15
O:MRUS240315P00025000 OPASPS Put American 100 25 BATO 2024-03-15
O:MRUS240315P00030000 OPASPS Put American 100 30 BATO 2024-03-15
O:MRUS240315P00035000 OPASPS Put American 100 35 BATO 2024-03-15
O:MRUS240315P00040000 OPASPS Put American 100 40 BATO 2024-03-15
O:MRUS240216C00040000 OCASPS Call American 100 40 BATO 2024-02-16
O:MRUS240216C00045000 OCASPS Call American 100 45 BATO 2024-02-16
O:MRUS240216C00050000 OCASPS Call American 100 50 BATO 2024-02-16
O:MRUS240216P00040000 OPASPS Put American 100 40 BATO 2024-02-16
O:MRUS240216P00045000 OPASPS Put American 100 45 BATO 2024-02-16
O:MRUS240216P00050000 OPASPS Put American 100 50 BATO 2024-02-16
O:MRUS240216C00012500 OCASPS Call American 100 12.5 BATO 2024-02-16
O:MRUS240216C00015000 OCASPS Call American 100 15 BATO 2024-02-16
O:MRUS240216C00017500 OCASPS Call American 100 17.5 BATO 2024-02-16
O:MRUS240216C00020000 OCASPS Call American 100 20 BATO 2024-02-16
O:MRUS240216C00022500 OCASPS Call American 100 22.5 BATO 2024-02-16
O:MRUS240216C00025000 OCASPS Call American 100 25 BATO 2024-02-16
O:MRUS240216C00030000 OCASPS Call American 100 30 BATO 2024-02-16
O:MRUS240216C00035000 OCASPS Call American 100 35 BATO 2024-02-16
O:MRUS240216P00012500 OPASPS Put American 100 12.5 BATO 2024-02-16
O:MRUS240216P00015000 OPASPS Put American 100 15 BATO 2024-02-16
O:MRUS240216P00017500 OPASPS Put American 100 17.5 BATO 2024-02-16
O:MRUS240216P00020000 OPASPS Put American 100 20 BATO 2024-02-16
O:MRUS240216P00022500 OPASPS Put American 100 22.5 BATO 2024-02-16
O:MRUS240216P00025000 OPASPS Put American 100 25 BATO 2024-02-16
O:MRUS240216P00030000 OPASPS Put American 100 30 BATO 2024-02-16
O:MRUS240216P00035000 OPASPS Put American 100 35 BATO 2024-02-16
O:MRUS240119C00045000 OCASPS Call American 100 45 BATO 2024-01-19
O:MRUS240119C00050000 OCASPS Call American 100 50 BATO 2024-01-19
O:MRUS240119P00045000 OPASPS Put American 100 45 BATO 2024-01-19
O:MRUS240119P00050000 OPASPS Put American 100 50 BATO 2024-01-19
O:MRUS240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:MRUS240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:MRUS240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:MRUS240119C00010000 OCASPS Call American 100 10 BATO 2024-01-19
O:MRUS240119C00012500 OCASPS Call American 100 12.5 BATO 2024-01-19
O:MRUS240119C00015000 OCASPS Call American 100 15 BATO 2024-01-19
O:MRUS240119C00017500 OCASPS Call American 100 17.5 BATO 2024-01-19
O:MRUS240119C00020000 OCASPS Call American 100 20 BATO 2024-01-19
O:MRUS240119C00022500 OCASPS Call American 100 22.5 BATO 2024-01-19
O:MRUS240119C00025000 OCASPS Call American 100 25 BATO 2024-01-19
O:MRUS240119C00030000 OCASPS Call American 100 30 BATO 2024-01-19
O:MRUS240119C00035000 OCASPS Call American 100 35 BATO 2024-01-19
O:MRUS240119C00040000 OCASPS Call American 100 40 BATO 2024-01-19
O:MRUS240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:MRUS240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:MRUS240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:MRUS240119P00010000 OPASPS Put American 100 10 BATO 2024-01-19
O:MRUS240119P00012500 OPASPS Put American 100 12.5 BATO 2024-01-19
O:MRUS240119P00015000 OPASPS Put American 100 15 BATO 2024-01-19
O:MRUS240119P00017500 OPASPS Put American 100 17.5 BATO 2024-01-19
O:MRUS240119P00020000 OPASPS Put American 100 20 BATO 2024-01-19
O:MRUS240119P00022500 OPASPS Put American 100 22.5 BATO 2024-01-19
O:MRUS240119P00025000 OPASPS Put American 100 25 BATO 2024-01-19
O:MRUS240119P00030000 OPASPS Put American 100 30 BATO 2024-01-19
O:MRUS240119P00035000 OPASPS Put American 100 35 BATO 2024-01-19
O:MRUS240119P00040000 OPASPS Put American 100 40 BATO 2024-01-19
O:MRUS231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:MRUS231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:MRUS231215C00010000 OCASPS Call American 100 10 BATO 2023-12-15
O:MRUS231215C00012500 OCASPS Call American 100 12.5 BATO 2023-12-15
O:MRUS231215C00015000 OCASPS Call American 100 15 BATO 2023-12-15
O:MRUS231215C00017500 OCASPS Call American 100 17.5 BATO 2023-12-15
O:MRUS231215C00020000 OCASPS Call American 100 20 BATO 2023-12-15
O:MRUS231215C00022500 OCASPS Call American 100 22.5 BATO 2023-12-15
O:MRUS231215C00025000 OCASPS Call American 100 25 BATO 2023-12-15
O:MRUS231215C00030000 OCASPS Call American 100 30 BATO 2023-12-15
O:MRUS231215C00035000 OCASPS Call American 100 35 BATO 2023-12-15
O:MRUS231215C00040000 OCASPS Call American 100 40 BATO 2023-12-15
O:MRUS231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:MRUS231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:MRUS231215P00010000 OPASPS Put American 100 10 BATO 2023-12-15
O:MRUS231215P00012500 OPASPS Put American 100 12.5 BATO 2023-12-15
O:MRUS231215P00015000 OPASPS Put American 100 15 BATO 2023-12-15
O:MRUS231215P00017500 OPASPS Put American 100 17.5 BATO 2023-12-15
O:MRUS231215P00020000 OPASPS Put American 100 20 BATO 2023-12-15
O:MRUS231215P00022500 OPASPS Put American 100 22.5 BATO 2023-12-15
O:MRUS231215P00025000 OPASPS Put American 100 25 BATO 2023-12-15
O:MRUS231215P00030000 OPASPS Put American 100 30 BATO 2023-12-15
O:MRUS231215P00035000 OPASPS Put American 100 35 BATO 2023-12-15
O:MRUS231215P00040000 OPASPS Put American 100 40 BATO 2023-12-15
O:MRUS231117C00012500 OCASPS Call American 100 12.5 BATO 2023-11-17
O:MRUS231117C00015000 OCASPS Call American 100 15 BATO 2023-11-17
O:MRUS231117C00017500 OCASPS Call American 100 17.5 BATO 2023-11-17
O:MRUS231117C00020000 OCASPS Call American 100 20 BATO 2023-11-17
O:MRUS231117C00022500 OCASPS Call American 100 22.5 BATO 2023-11-17
O:MRUS231117C00025000 OCASPS Call American 100 25 BATO 2023-11-17
O:MRUS231117C00030000 OCASPS Call American 100 30 BATO 2023-11-17
O:MRUS231117C00035000 OCASPS Call American 100 35 BATO 2023-11-17
O:MRUS231117P00012500 OPASPS Put American 100 12.5 BATO 2023-11-17
O:MRUS231117P00015000 OPASPS Put American 100 15 BATO 2023-11-17
O:MRUS231117P00017500 OPASPS Put American 100 17.5 BATO 2023-11-17
O:MRUS231117P00020000 OPASPS Put American 100 20 BATO 2023-11-17
O:MRUS231117P00022500 OPASPS Put American 100 22.5 BATO 2023-11-17
O:MRUS231117P00025000 OPASPS Put American 100 25 BATO 2023-11-17
O:MRUS231117P00030000 OPASPS Put American 100 30 BATO 2023-11-17
O:MRUS231117P00035000 OPASPS Put American 100 35 BATO 2023-11-17
O:MRUS231020C00035000 OCASPS Call American 100 35 BATO 2023-10-20
O:MRUS231020P00035000 OPASPS Put American 100 35 BATO 2023-10-20
O:MRUS231020C00012500 OCASPS Call American 100 12.5 BATO 2023-10-20
O:MRUS231020C00015000 OCASPS Call American 100 15 BATO 2023-10-20
O:MRUS231020C00017500 OCASPS Call American 100 17.5 BATO 2023-10-20
O:MRUS231020C00020000 OCASPS Call American 100 20 BATO 2023-10-20
O:MRUS231020C00022500 OCASPS Call American 100 22.5 BATO 2023-10-20
O:MRUS231020C00025000 OCASPS Call American 100 25 BATO 2023-10-20
O:MRUS231020C00030000 OCASPS Call American 100 30 BATO 2023-10-20
O:MRUS231020P00012500 OPASPS Put American 100 12.5 BATO 2023-10-20
O:MRUS231020P00015000 OPASPS Put American 100 15 BATO 2023-10-20
O:MRUS231020P00017500 OPASPS Put American 100 17.5 BATO 2023-10-20
O:MRUS231020P00020000 OPASPS Put American 100 20 BATO 2023-10-20
O:MRUS231020P00022500 OPASPS Put American 100 22.5 BATO 2023-10-20
O:MRUS231020P00025000 OPASPS Put American 100 25 BATO 2023-10-20
O:MRUS231020P00030000 OPASPS Put American 100 30 BATO 2023-10-20
O:MRUS230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:MRUS230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:MRUS230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:MRUS230915C00010000 OCASPS Call American 100 10 BATO 2023-09-15
O:MRUS230915C00012500 OCASPS Call American 100 12.5 BATO 2023-09-15
O:MRUS230915C00015000 OCASPS Call American 100 15 BATO 2023-09-15
O:MRUS230915C00017500 OCASPS Call American 100 17.5 BATO 2023-09-15
O:MRUS230915C00020000 OCASPS Call American 100 20 BATO 2023-09-15
O:MRUS230915C00022500 OCASPS Call American 100 22.5 BATO 2023-09-15
O:MRUS230915C00025000 OCASPS Call American 100 25 BATO 2023-09-15
O:MRUS230915C00030000 OCASPS Call American 100 30 BATO 2023-09-15
O:MRUS230915C00035000 OCASPS Call American 100 35 BATO 2023-09-15
O:MRUS230915C00040000 OCASPS Call American 100 40 BATO 2023-09-15
O:MRUS230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:MRUS230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:MRUS230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:MRUS230915P00010000 OPASPS Put American 100 10 BATO 2023-09-15
O:MRUS230915P00012500 OPASPS Put American 100 12.5 BATO 2023-09-15
O:MRUS230915P00015000 OPASPS Put American 100 15 BATO 2023-09-15
O:MRUS230915P00017500 OPASPS Put American 100 17.5 BATO 2023-09-15
O:MRUS230915P00020000 OPASPS Put American 100 20 BATO 2023-09-15
O:MRUS230915P00022500 OPASPS Put American 100 22.5 BATO 2023-09-15
O:MRUS230915P00025000 OPASPS Put American 100 25 BATO 2023-09-15
O:MRUS230915P00030000 OPASPS Put American 100 30 BATO 2023-09-15
O:MRUS230915P00035000 OPASPS Put American 100 35 BATO 2023-09-15
O:MRUS230915P00040000 OPASPS Put American 100 40 BATO 2023-09-15
O:MRUS230818C00012500 OCASPS Call American 100 12.5 BATO 2023-08-18
O:MRUS230818C00015000 OCASPS Call American 100 15 BATO 2023-08-18
O:MRUS230818C00017500 OCASPS Call American 100 17.5 BATO 2023-08-18
O:MRUS230818C00020000 OCASPS Call American 100 20 BATO 2023-08-18
O:MRUS230818C00022500 OCASPS Call American 100 22.5 BATO 2023-08-18
O:MRUS230818C00025000 OCASPS Call American 100 25 BATO 2023-08-18
O:MRUS230818C00030000 OCASPS Call American 100 30 BATO 2023-08-18
O:MRUS230818C00035000 OCASPS Call American 100 35 BATO 2023-08-18
O:MRUS230818P00012500 OPASPS Put American 100 12.5 BATO 2023-08-18
O:MRUS230818P00015000 OPASPS Put American 100 15 BATO 2023-08-18
O:MRUS230818P00017500 OPASPS Put American 100 17.5 BATO 2023-08-18
O:MRUS230818P00020000 OPASPS Put American 100 20 BATO 2023-08-18
O:MRUS230818P00022500 OPASPS Put American 100 22.5 BATO 2023-08-18
O:MRUS230818P00025000 OPASPS Put American 100 25 BATO 2023-08-18
O:MRUS230818P00030000 OPASPS Put American 100 30 BATO 2023-08-18
O:MRUS230818P00035000 OPASPS Put American 100 35 BATO 2023-08-18
Flux d'actualités
News Merus
Merus présente les résultats financiers pour le deuxième trimestre 2024 et informe sur le déroulement actuel des opérations.
Merus, une société d'oncologie au stade clinique, a publié ses résultats financiers du deuxième trimestre 2024 et a fourni des mises à jour sur son pipeline, y compris les progrès réalisés avec le candidat principal Petosemtamab dans le cancer de la tête et du cou et le cancer colorectal, ainsi que des mises à jour sur d'autres programmes tels que Zenocutuzumab et MCLA-129.
GlobeNewswire Inc. • Il y a 2 mois
News Clinical Study
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of a poster regarding MCLA-129 presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.
GlobeNewswire Inc. • Il y a 4 mois
News Clinical Study
MCLA-129 von Merus zeigt in Posterpräsentation auf der ASCO®-Jahrestagung 2024 eine vielversprechende Wirksamkeit als Einzelwirkstoff bei METex14-NSCLC
UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) („Merus“, das „Unternehmen“, „wir“ oder „unser“), ein Unternehmen aus dem Bereich der klinischen Onkologie, das innovative multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, hat heute die Veröffentlichung eines Posters zu MCLA-129 bekanntgegeben, das auf der Jahrestagung 2024 der American Society of Clinical Oncology® (ASCO®) vorgestellt wurde, die vom 31. Mai bis 4. Juni 2024 in Chicago stattfindet.
GlobeNewswire Inc. • Il y a 4 mois
News Clinical Study
L’anticorps MCLA-129 produit par Merus ou la promesse d’une monothérapie efficace dans le traitement du CPNPC présentant une mutation de l’exon 14 du gène MET - une présentation sous forme de poster est prévue lors du congrès annuel 2024 de l’ASCO®
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 03 juin 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après « Merus, la Société, nous, ou notre », une société spécialisée dans l’oncologie au stade clinique développant les anticorps multispécifiques innovants de pleine longueur Biclonics® et Triclonics®, annonce ce jour qu’elle présentera des données relatives au MCLA-129 sous la forme d’un poster lors du congrès annuel 2024 de l’organisation professionnelle américaine des oncologues, l’American Society of Clinical Oncology®, ou ASCO® se déroulant à Chicago du 31 mai au 4 juin.
GlobeNewswire Inc. • Il y a 4 mois
Calendar Calendar of Events
Merus präsentiert Zwischenergebnisse zu MCLA-145 als Monotherapie und in Kombination mit Pembrolizumab auf der ASCO®-Jahrestagung 2024
UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) („Merus“, das „Unternehmen“, „wir“ oder „unser“), ein Unternehmen aus dem Bereich der klinischen Onkologie, das innovative multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, hat heute aktualisierte klinische Zwischenergebnisse zu MCLA-145 als Monotherapie und in Kombination mit Pembrolizumab auf der Jahrestagung 2024 der American Society of Clinical Oncology® (ASCO®) bekanntgegeben, die vom 31. Mai bis 4. Juni 2024 in Chicago stattfindet.
GlobeNewswire Inc. • Il y a 4 mois
Calendar Calendar of Events
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.
GlobeNewswire Inc. • Il y a 4 mois
Calendar Calendar of Events
Merus : présentation des données provisoires sur le MCLA-145 en monothérapie et en association avec le pembrolizumab lors du congrès annuel 2024 de l’ASCO®
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 02 juin 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après « Merus, la Société, nous, ou notre », une société spécialisée dans l’oncologie au stade clinique développant les anticorps multispécifiques innovants de pleine longueur Biclonics® et Triclonics®, annonce ce jour avoir présenté les nouvelles données cliniques provisoires sur le MCLA-145 en monothérapie et en association avec le pembrolizumab au congrès annuel 2024 de l’organisation professionnelle américaine des oncologues, l’American Society of Clinical Oncology®, ou ASCO® se déroulant à Chicago du 31 mai au 4 juin.
GlobeNewswire Inc. • Il y a 4 mois
Stocks Changes in company's own shares
Merus Announces Pricing of Upsized Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up to an additional 1,132,500 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters’ option to purchase the Option Shares, are expected to be approximately $400.2 million. All of the shares in the offering are to be sold by Merus.
GlobeNewswire Inc. • Il y a 4 mois
Calendar Calendar of Events
Merus nimmt an Kamingespräch auf der Jefferies Global Healthcare Conference teil
UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen aus dem Bereich der klinischen Onkologie, das innovative multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, gab heute bekannt, dass Dr. Bill Lundberg, President und Chief Executive Officer von Merus, am Mittwoch, den 5. Juni 2024 um 11:00 Uhr ET an einem Kamingespräch auf der Jefferies Global Healthcare Conference teilnehmen wird.
GlobeNewswire Inc. • Il y a 4 mois
Calendar Calendar of Events
Participation de Merus à un échange informel à l’occasion de la conférence Jefferies Global Healthcare
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 29 mai 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une société d’oncologie au stade clinique développant des anticorps pleine longueur multispécifiques et novateurs, Biclonics® et Triclonics®, annonce ce jour que son Président et directeur générale, Bill Lundberg, docteur en médecine, prendra part à la conférence Jefferies Global Healthcare le mercredi 5 juin 2024 à 11h00, heure de l’Est.
GlobeNewswire Inc. • Il y a 4 mois
Voir tous
Actualités liées
Dernières actualités

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT